Patents by Inventor Chia-Yang Lin

Chia-Yang Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEDIA LIBRARY USER INTERFACES
    Publication number: 20250258686
    Abstract: The present disclosure generally relates to navigation, display, and/or presentation of content.
    Type: Application
    Filed: September 26, 2024
    Publication date: August 14, 2025
    Inventors: Craig M. Federighi, Nicole R. RYAN, Chia Yang LIN, Jingfang CHEN, Aaron MORING, William A. SORRENTINO, III, Simon BOVET, Denys STAS, Matthieu LUCAS, Graham R. Clarke, Andreas J. Karlsson
  • Antigen binding molecule formats
    Patent number: 12331109
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Grant
    Filed: April 19, 2024
    Date of Patent: June 17, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • IL2 agonists and methods of use thereof
    Patent number: 12319724
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: June 3, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
    Publication number: 20250171545
    Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Application
    Filed: January 23, 2025
    Publication date: May 29, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Ann-Hwee LEE, Yan YANG, Chia-Yang LIN
  • Compositions and methods for treating cytokine release syndrome
    Patent number: 12274747
    Abstract: The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 15, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kara Olson, Olga Sineshchekova, Eric Smith, Chia-Yang Lin
  • CHIMERIC HEAVY CHAIN CONSTANT DOMAINS WITH REDUCED BINDING TO FC GAMMA RECEPTORS AND USES THEREOF
    Publication number: 20250109207
    Abstract: The present disclosure relates to chimeric heavy chain constant domains having reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Nucleic acids encoding such recombinant polypeptides are also disclosed, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.
    Type: Application
    Filed: April 20, 2023
    Publication date: April 3, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Naga Suhasini AVVARU, Samuel DAVIS, Chia-Yang LIN, Yang SHEN
  • NOVEL ANTIGEN BINDING MOLECULE FORMATS
    Publication number: 20250109194
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: December 11, 2024
    Publication date: April 3, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong ZHANG, Samuel DAVIS, Chia-Yang LIN, Eric SMITH, Erica PYLES, Michael ROSCONI, Nina LIU, Supriya PATEL, Andrew J. MURPHY
  • User interfaces for messaging conversations
    Patent number: 12255857
    Abstract: In some embodiments, an electronic device displays a plurality of content items in a messaging conversation. In some embodiments, the electronic device displays user interfaces associated with one or more content items in a messaging conversation.
    Type: Grant
    Filed: January 29, 2024
    Date of Patent: March 18, 2025
    Assignee: Apple Inc.
    Inventors: Zheng Xuan Hong, Chia Yang Lin, Chanaka G. Karunamuni, Nicole R. Ryan, Graham R. Clarke
  • N-terminal scFv multispecific binding molecules
    Patent number: 12240907
    Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 4, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang Shen, Ann-Hwee Lee, Yan Yang, Chia-Yang Lin
  • N-terminal scFv multispecific binding molecules
    Patent number: 12240908
    Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: March 4, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang Shen, Ann-Hwee Lee, Yan Yang, Chia-Yang Lin
  • IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20250066441
    Abstract: The present disclosure relates to IL 12 receptor agonists with improved therapeutic profiles.
    Type: Application
    Filed: July 18, 2022
    Publication date: February 27, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Aaron CHANG, Jiaxi WU, Tong ZHANG, Nicolin BLOCH, Erica ULLMAN, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • IgG Fc-IL2-R?-IL2 fusions and methods of use thereof
    Patent number: 12215131
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: February 4, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20250034224
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: April 5, 2024
    Publication date: January 30, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric Smith, Chia-Yang LIN, Thomas Craig Meagher
  • CIRCULARIZED ANTIBODY MOLECULES
    Publication number: 20250011449
    Abstract: The present disclosure provides circularized antibody molecules and methods of their production and use.
    Type: Application
    Filed: June 10, 2024
    Publication date: January 9, 2025
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tri NGUYEN, Samarthaben Jayeshkumar PATEL, Yang SHEN, Chia-Yang LIN
  • Antigen binding molecule formats
    Patent number: 12180272
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: December 31, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20240425609
    Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.
    Type: Application
    Filed: November 9, 2022
    Publication date: December 26, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Bei WANG, Naga Suhasini AVVARU, Chia-Yang LIN, Andrew J. MURPHY, Aynur HERMANN, Jee H. KIM
  • NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20240400632
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: August 19, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20240400687
    Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as nucleic acids encoding such molecules, pharmaceutical compositions comprising such molecules, and methods of use thereof. In certain aspects, disclosed are CD20-PD1 binding molecules comprising at least one CD20 targeting moiety and at least one PD1 agonist moiety, where in certain aspects the PD1 agonist moiety is a PDL1 or PDL2 ectodomain or a PD1 binding portion thereof.
    Type: Application
    Filed: May 10, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Bei WANG, Naga Suhasini AVVARU, Chia-Yang LIN, Andrew J. MURPHY
  • Display screen or portion thereof with animated graphical user interface
    Patent number: D1059397
    Type: Grant
    Filed: February 7, 2024
    Date of Patent: January 28, 2025
    Assignee: Apple Inc.
    Inventors: Gorm Halfdan Amand, Daniel Joseph Billett, Joseph Chan, Elizabeth Caroline Cranfill, James Nicholas Jones, Ieyuki Kawashima, Vincent M. Lane, Chia Yang Lin, Cecilia S. Zhou
  • Display screen or portion thereof with graphical user interface
    Patent number: D1087151
    Type: Grant
    Filed: June 4, 2023
    Date of Patent: August 5, 2025
    Assignee: Apple Inc.
    Inventors: Jesse Chand, Jonathan R. Dascola, Stephen O. Lemay, Chia Yang Lin, Richard D. Lyons, Israel Pastrana Vicente, Lorena S. Pazmino, William A. Sorrentino, III, Matan Stauber